Linked Life Data

11354701

Source:http://linkedlifedata.com/resource/pubmed/id/11354701

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11354701rdf:typepubmed:Citationlld:pubmed
pubmed-article:11354701lifeskim:mentionsumls-concept:C0014544lld:lifeskim
pubmed-article:11354701lifeskim:mentionsumls-concept:C0231335lld:lifeskim
pubmed-article:11354701lifeskim:mentionsumls-concept:C0076829lld:lifeskim
pubmed-article:11354701lifeskim:mentionsumls-concept:C1552617lld:lifeskim
pubmed-article:11354701lifeskim:mentionsumls-concept:C0282443lld:lifeskim
pubmed-article:11354701pubmed:issue4lld:pubmed
pubmed-article:11354701pubmed:dateCreated2001-5-16lld:pubmed
pubmed-article:11354701pubmed:abstractTextTopiramate is an antiepileptic drug (AED) which appears to have a broad range of antiseizure activity in humans. A previous overview focused primarily on results of trials of topiramate in adults with epilepsy, and this review highlights the use of topiramate in children. Clinical trials have shown that topiramate is effective when used adjunctively in children with refractory partial-onset seizures and generalised tonic-clonic seizures. The drug significantly reduced seizure frequency compared with placebo in children with partial-onset epilepsy after 16 weeks of double-blind adjunctive treatment (33.1 vs 10.5%); the frequency of secondarily generalised seizures was also markedly reduced. During a nonblind extension of this trial, the mean dosage was titrated from 4.8 to 9 mg/kg/day and further reductions in the frequency of seizures were observed (71% compared with prestudy levels). In 2 mixed adult/paediatric populations with primary generalised tonic-clonic seizures, topiramate (target dosage 5.2 to 9.3 mg/kg/day) reduced the seizure rate compared with those receiving placebo. This difference was significant in one trial (56.7 vs 9%) but not in another (57.1 vs 33.2%). A subanalysis of the paediatric patients found that the favourable effect of topiramate on seizure rates was not age-related. Topiramate (median average dosage 5.1 mg/kg/day) was also found to be useful as adjunctive therapy in the management of Lennox-Gastaut syndrome and significantly reduced the mean frequency of drop attacks by 14.8% compared with an increase of 5.1% with placebo. Further gains in seizure control were made in a nonblind extension of this trial where the mean topiramate dosage was 10 mg/kg/day. Nine of 11 patients in 1 pilot trial of children with otherwise intractable West syndrome, and 5 of 10 in another, achieved a > or =50% reduction in seizure rate with topiramate (target dosage up to 24 mg/kg/day). In an 18-month extension of the former trial (mean dosage 29 mg/kg/day) a > or =50% reduction in seizures was maintained in 7 of 11 children. Adverse events associated with adjunctive topiramate therapy in children were predominantly neuropsychiatric and generally mild to moderate in severity. Behavioural and cognitive problems do occur and are a limiting factor in some children. Also, weight loss can be problematical in some individuals. Withdrawal rates were low in the controlled trials (4.8%), but appear to be more frequent in noncomparative and post-marketing studies. CONCLUSION: Well controlled studies have demonstrated that topiramate is an effective agent for the adjunctive therapy of partial and generalised tonic-clonic seizures in children. Treatment-limiting adverse events do occur, but these may be managed by slow titration. Although comparative studies with the other newer AEDs used in adjuntive therapy are required, topiramate is an important extension to the range of drugs that may be used to treat refractory epilepsy in children.lld:pubmed
pubmed-article:11354701pubmed:languageenglld:pubmed
pubmed-article:11354701pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11354701pubmed:citationSubsetIMlld:pubmed
pubmed-article:11354701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11354701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11354701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11354701pubmed:statusMEDLINElld:pubmed
pubmed-article:11354701pubmed:issn1174-5878lld:pubmed
pubmed-article:11354701pubmed:authorpubmed-author:OrmrodDDlld:pubmed
pubmed-article:11354701pubmed:authorpubmed-author:McClellanKKlld:pubmed
pubmed-article:11354701pubmed:issnTypePrintlld:pubmed
pubmed-article:11354701pubmed:volume3lld:pubmed
pubmed-article:11354701pubmed:ownerNLMlld:pubmed
pubmed-article:11354701pubmed:authorsCompleteYlld:pubmed
pubmed-article:11354701pubmed:pagination293-319lld:pubmed
pubmed-article:11354701pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:meshHeadingpubmed-meshheading:11354701...lld:pubmed
pubmed-article:11354701pubmed:year2001lld:pubmed
pubmed-article:11354701pubmed:articleTitleTopiramate: a review of its use in childhood epilepsy.lld:pubmed
pubmed-article:11354701pubmed:affiliationAdis International Limited, Auckland, New Zealand. demail@adis.co.nzlld:pubmed
pubmed-article:11354701pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11354701pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11354701lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11354701lld:pubmed